Home/Filings/4/0001209191-21-049373

4//SEC Filing

BIOS Fund III QP, LP 4

Accession 0001209191-21-049373

CIK 0001740279other

View on SEC.gov Company Profile

Filed

Aug 2, 8:00 PM ET

Accepted

Aug 3, 4:53 PM ET

Size

46.0 KB

Accession

0001209191-21-049373

Insider Transaction Report

Form 4

Period: 2021-08-03

IN8BIO, INC.INAB

BIOS Fund III NT, LP

10% Owner

Transactions

Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)
Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)

BIOS Fund III QP, LP

10% Owner

Transactions

Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)

BIOS Capital Management, LP

10% Owner

Transactions

Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)
Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)

BIOS Advisors GP, LLC

10% Owner

Transactions

Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)
Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)

Fletcher Aaron G.L.

10% Owner

Transactions

Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)
Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)
Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)
Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)

BIOS Fund III, LP

10% Owner

Transactions

Conversion
Common Stock
2021-08-03+574,432→ 574,432 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+997,433→ 997,433 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+2,225,316→ 2,225,316 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+359,374→ 359,374 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−1,706,490→ 0 total(indirect: See footnote)
→ Common Stock (1,876,624 underlying)
Conversion
Series A Preferred Stock
2021-08-03−309,823→ 0 total(indirect: See footnote)
→ Common Stock (340,712 underlying)
Conversion
Series A Preferred Stock
2021-08-03−2,023,568→ 0 total(indirect: See footnote)
→ Common Stock (2,225,316 underlying)
Conversion
Common Stock
2021-08-03+1,876,624→ 1,876,624 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+251,211→ 251,211 total(indirect: See footnote)
Conversion
Common Stock
2021-08-03+340,712→ 340,712 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2021-08-03−907,007→ 0 total(indirect: See footnote)
→ Common Stock (997,433 underlying)
Conversion
Series A Preferred Stock
2021-08-03−326,795→ 0 total(indirect: See footnote)
→ Common Stock (359,374 underlying)
Conversion
Series A Preferred Stock
2021-08-03−522,355→ 0 total(indirect: See footnote)
→ Common Stock (574,432 underlying)
Conversion
Series A Preferred Stock
2021-08-03−228,438→ 0 total(indirect: See footnote)
→ Common Stock (251,211 underlying)

Footnotes (12)

[F1]Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
[F10]The securities are directly held by Bios Fund III.
[F11]The securities are directly held by Bios Fund III QP.
[F12]The securities are directly held by Bios Fund III NT.
[F2]The securities are directly held by Bios Fund II, LP ("Bios Fund II").
[F3]Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
[F4]Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
[F5]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
[F6]Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
[F7]The securities are directly held by Bios Fund II QP.
[F8]The securities are directly held by Bios Fund II NT.
[F9]The securities are directly held by BIOS Incysus.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

IN8BIO, INC.

CIK 0001740279

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001791916

Filing Metadata

Form type: 4
Filed: Aug 2, 8:00 PM ET
Accepted: Aug 3, 4:53 PM ET
Size: 46.0 KB

View on SEC.gov